Results of an autopsy-based study revealed that sudden cardiac death and multiorgan pathology may be more closely linked to SSc than previously thought.

Although the SYMMETRY Phase IIb trial of the FGF21 analogue efruxifermin did not meet its primary endpoint at 36 weeks, ...

He, L., Zhou, Y., Wang, Q.T., Liu, J. and Ma, J.P. (2025) Two Pathological Patterns in Different Stages of the Same Disease. Journal of Biosciences and Medicines, 13, 189-195. doi: ...

Over the coming months, the Pulmonary Fibrosis Foundation's 2025 PFF Walk will aim to raise more than $1 million for the ...

Announcing a new article publication for BIO Integration journal. Liver fibrosis is caused by excessive extracellular matrix ...

Disclaimer: AlphaGalileo is not responsible for the accuracy of content posted to AlphaGalileo by contributing institutions or for the use of any information through the AlphaGalileo system.

Myocardial fibrosis was significantly more common among individuals with SSc vs controls (82% vs 31%; OR, 10.7; 95% CI, 4.1-28.7; P <.01). Fibrosis could not be explained by coronary artery disease, ...

Looking at combined benefits, a third of patients taking semaglutide were able to see both resolution of steatohepatitis and reduction of liver fibrosis (32.7%), compared with 16.1% of patients ...

Interim results from the Phase III ESSENCE trial published in The New England Journal of Medicine show once-weekly semaglutide improved liver histology, metabolic markers, and weight loss in patients ...